IL-17A/CEBPβ/OPN/LYVE-1 axis inhibits anti-tumor immunity by promoting tumor-associated tissue-resident macrophages
Cell Reports · 2024-12 · 43 (12) · 115039
DOI: 10.1016/j.celrep.2024.115039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2024-12. Verfasst von Lei Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Organ Regeneration & Transplantation of the Ministry of Education, The First Hospital of Jilin University, Changchun, China; Nation…. Hauptthemen laut MEDLINE: Interleukin-17, Osteopontin, Tumor-Associated Macrophages, CCAAT-Enhancer-Binding Protein-beta. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Jilin Provincial Natural Science Foundation, National Key Research and Development Program of China.
Abstract (Originalsprache)
Tumor-associated macrophages (TAMs) are a critical component of the immunosuppressive tumor microenvironment, comprising monocyte-derived macrophages (MDM-TAMs) and tissue-resident macrophages (TRM-TAMs). Here, we discovered that TRM-TAMs mediate the pro-tumor effects of interleukin (IL)-17A and that IL-17A-driven tumor progression requires tumor cell production of osteopontin (OPN). Mechanistically, we identified CEBPβ as a transcription factor downstream of IL-17A in tumor cells and LYVE-1 as an OPN receptor on TRM-TAMs. IL-17A stimulates tumor cell production of OPN, and OPN/LYVE-1 signaling activates the JNK/c-Jun pathway, leading to the proliferation of immunosuppressive LYVE-1+ TRM-TAMs. Unlike its effect on LYVE-1+ TRM-TAMs, OPN interacts with α4β1 to promote the chemotaxis of LYVE-1- MDM-TAMs toward tumors. IL-17A neutralization, OPN inactivation in tumor cells, or LYVE-1 deletion in macrophages inhibited TAMs and enhanced anti-tumor immune responses and anti-PDL1 therapy. Thus, the IL-17A/CEBPβ/OPN/LYVE-1 axis offers a mechanism suppressing anti-tumor immune responses and, hence, an effective therapeutic target for cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Organ Regeneration & Transplantation of the Ministry of Education, The First Hospital of Jilin University, Changchun, China; National-local Joint Engineering Laboratory of Animal Models for Human Disea…
Förderung
- National Natural Science Foundation of China
- Jilin Provincial Natural Science Foundation
- National Key Research and Development Program of China
- JiangXi Province Human Resources and Social Security Department
- Key Technologies Research and Development Program
Zitieren
APA
Zhao, L., Wang, Z., Tan, Y., Ma, J., Huang, W., Zhang, X., Jin, C., Zhang, T., Liu, W., & Yang, Y. G. (2024). IL-17A/CEBPβ/OPN/LYVE-1 axis inhibits anti-tumor immunity by promoting tumor-associated tissue-resident macrophages. Cell Reports, 43(12), 115039. https://doi.org/10.1016/j.celrep.2024.115039
Vancouver
Zhao L, Wang Z, Tan Y, Ma J, Huang W, Zhang X, et al. IL-17A/CEBPβ/OPN/LYVE-1 axis inhibits anti-tumor immunity by promoting tumor-associated tissue-resident macrophages. Cell Reports. 2024;43(12):115039. doi:10.1016/j.celrep.2024.115039
BibTeX
@article{Zhao2024,
author = {Zhao, Lei and Wang, Zonghan and Tan, Yuying and Ma, Jianan and Huang, Wei and Zhang, Xiaoying and Jin, Chunhui and Zhang, Ting and Liu, Wentao and Yang, Yong-Guang},
title = {IL-17A/CEBPβ/OPN/LYVE-1 axis inhibits anti-tumor immunity by promoting tumor-associated tissue-resident macrophages},
journal = {Cell Reports},
year = {2024},
volume = {43},
number = {12},
pages = {115039},
doi = {10.1016/j.celrep.2024.115039}
}
EUVIMED